Literature DB >> 7551220

Structure and properties of aluminum-containing adjuvants.

S L Hem1, J L White.   

Abstract

This chapter is concerned with the identification, characterization, and behavior of aluminum-containing adjuvants with proteins and anions similar to those occurring in vaccines and interstitial fluid. Aluminum-containing adjuvants referred to commercially as aluminum hydroxide have been identified as poorly crystalline aluminum oxyhydroxide with the structure of the mineral boehmite. Relevant properties of this material include its high surface area and its high pI, which provide the adjuvant with a high adsorptive capacity for positively charged proteins. Aluminum phosphate and alum-precipitated adjuvants may be classified as amorphous aluminum hydroxyphosphate with little or no specifically adsorbed sulfate. Variations in the molar PO4/A1 ratio of amorphous aluminum hydroxyphosphates result in PI values that range from 5 up to 7; the materials are negatively charged at a physiological pH of 7.4. The amorphous nature of these compounds gives them high surface area and high protein adsorptive capacity for positively charged proteins. Observations on the interactions of anions and charged proteins with charged adjuvant surfaces have provided a framework for predicting behavior of complex systems of vaccines and for designing specific combinations of adjuvants and antigens to optimize the stability and efficacy of vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551220     DOI: 10.1007/978-1-4615-1823-5_9

Source DB:  PubMed          Journal:  Pharm Biotechnol        ISSN: 1078-0467


  10 in total

Review 1.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

Review 2.  Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen.

Authors:  Mohammed Ali Dahhas; Mohammad A Alsenaidy
Journal:  Saudi Pharm J       Date:  2022-02-25       Impact factor: 4.562

3.  Disparate adjuvant properties among three formulations of "alum".

Authors:  Derek W Cain; Sergio E Sanders; Michael M Cunningham; Garnett Kelsoe
Journal:  Vaccine       Date:  2012-11-29       Impact factor: 3.641

4.  Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

Authors:  Shinobu Watarai; Tana Iwase; Tomoko Tajima; Eiji Yuba; Kenji Kono
Journal:  ScientificWorldJournal       Date:  2013-02-04

5.  The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.

Authors:  Tirth Raj Ghimire
Journal:  Springerplus       Date:  2015-04-16

Review 6.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

7.  Superovulation with a single administration of FSH in aluminum hydroxide gel: a novel superovulation method for cattle.

Authors:  Koji Kimura
Journal:  J Reprod Dev       Date:  2016-07-11       Impact factor: 2.214

8.  Vaccine adjuvants: mode of action.

Authors:  Ennio De Gregorio; Elena Caproni; Jeffrey B Ulmer
Journal:  Front Immunol       Date:  2013-07-31       Impact factor: 7.561

9.  Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.

Authors:  Robert E Haupt; Erin M Harberts; Robert J Kitz; Shirin Strohmeier; Florian Krammer; Robert K Ernst; Matthew B Frieman
Journal:  Vaccine       Date:  2021-08-03       Impact factor: 4.169

Review 10.  Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.

Authors:  Giuseppe Stefanetti; Francesco Borriello; Barbara Richichi; Ivan Zanoni; Luigi Lay
Journal:  Front Cell Infect Microbiol       Date:  2022-01-18       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.